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The cost-effectiveness of cyclooxygenase-2 (COX-2)
inhibitors over traditional non-steroidal anti-
inﬂammatory drugs (NSAIDs) has not been demonstrated
in the general population. There is signiﬁcant evidence 
to support that risk factors such as age, gastrointestinal
event history and NSAID intolerance alone or in combi-
nation can increase the rate of clinically signiﬁcant upper
gastrointestinal events (CSUGIE).
OBJECTIVES: This pharmacoeconomic model compares
the cost-effectiveness proﬁles of NSAIDs, rofecoxib and
celecoxib therapies in populations at high risk of CSUGIE
from the perspective of Veteran Affairs (VA) Healthcare
System.
METHODS: Data was reviewed from published post-
marketing outcome trials and FDA reviews of rofecoxib
and celecoxib compared to naproxen, ibuprofen, and
diclofenac and incorporated into an event targeted one-
year decision model. Gastrointestinal (GI) event rates
were stratiﬁed by high-risk subgroups receiving chronic
treatment for arthritic conditions. Additionally, dyspep-
sia, renal toxicity, and cardiovascular adverse event rates
were included to capture a comprehensive representation
of safety for all agents compared. Sensitivity analysis was
performed on all major indices based on variations in
results found in reviewed studies.
RESULTS: In spite of the substantial differences in GI
event rates for the following high-risk subgroups of 
age ((NSAIDS: 8.63–12.7%, celecoxib and rofecoxib:
3.54–7.9%), history of CSUGIE (NSAIDS: 11.8–15.3%,
celecoxib 7.8%, rofecoxib 6.72%) and previous NSAID
intolerance (NSAIDS: 3.89–7.8%, celecoxib 8.0%, 
rofecoxib1.87%), NSAIDs remain more cost-effective. In
non-aspirin patients, inclusion of myocardial infarction
(MI) event rates (NSAIDS: 0.15%, celecoxib 0.53%, rofe-
coxib 0.74%) resulted in higher cost for patients receiv-
ing rofecoxib. The primary cost drivers identiﬁed were
CSUGIEs, hospitalizations, and differences in cardiovas-
cular toxicity, speciﬁcally rates of congestive heart failure
and MI.
CONCLUSIONS: Inclusion of overall safety data in high-
risk populations did not alter the cost effectiveness of
NSAIDs compared to COX-2 inhibitors as the primary
therapy in treatment of arthritis patients in the VA
Healthcare System.
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Osteoporosis is a large and growing disease category with
signiﬁcant health consequences. Information on the cost-
effectiveness of preventing and treating this disease may
help healthcare payers allocate resources more efﬁciently.
OBJECTIVE: To assess cost-effectiveness of bisphospho-
nate therapies in multiple populations, subject to a value
threshold.
METHODS: A fracture incidence-based Markov model
of osteoporosis, where patients transition across outcome
states over time (e.g., fracture, healthy, dead), was used
to estimate incremental cost per QALY gained ratios. The
base case analysis was conducted on a cohort of women
aged 65 years with low bone mineral density (BMD) 
and prevalent vertebral fracture, with 3 years of treatment
with Actonel or Fosamax, using a 3-year time horizon.
Model inputs included fracture incidence rates, relative
risk (RR) reduction of fracture due to risk factors, frac-
ture costs, prices/day (Actonel $1.95; Fosamax $2.21),
health utilities, and efﬁcacy in terms of relative risk (RR)
of fracture reductions for hip (60% Actonel; 51%
Fosamax) and vertebral (49% Actonel; 47% Fosamax).
A 3% discount rate was applied to costs and outcomes.
Multiple populations were evaluated by varying efﬁcacy
rates (upper/lower 95% conﬁdence intervals), fracture
costs (+/-25%), utility values (+/-50%), fracture RR
(2.0–7.0), age (55–75), therapy discontinuation (0%–
76%), and time horizon (to lifetime).
RESULTS: Using a $30,000 per QALY gained cost-
effectiveness threshold, Actonel compared to no treat-
ment was cost-effective in the majority of populations.
Under base case assumptions Actonel’s cost/QALY gained
was $16,158 and dominated Fosamax (i.e., less costly
and more effective). Actonel’s cost/QALY ratio crossed
the threshold as RR of fracture declined (<5), starting
cohort age fell (<62), discontinuation rose, fracture costs
decreased (>25%), or fracture-related utility decrements
decreased (>50%).
CONCLUSIONS: Many high-risk patient subpopula-
tions can be treated economically with bisphophonates.
The most signiﬁcant drivers are RR of fracture, starting
cohort age and time horizon.
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